The coronavirus outbreak, which originated in Wuhan, China, is spreading worldwide. Credit: CDC on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Emory University in the US has announced that an antiviral drug candidate, EIDD-2801, may help treat patients with new coronavirus.

The university’s wholly-owned non-profit unit Drug Innovation Ventures at Emory (DRIVE) is developing the drug candidate.

EIDD-2801 is an oral ribonucleoside analogue, which blocks RNA viral replication in influenza, Ebola, respiratory syncytial virus and chikungunya.

The University of North Carolina and Vanderbilt University Medical Center tested the drug candidate.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Findings reveal that its active form, EIDD-1931 demonstrates efficacy against Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) viruses, related to the new virus.

Vanderbilt University School of Medicine pediatric infectious diseases director Mark Denison said: “Our studies in the Journal of Virology show potent activity of the EIDD-2801 parent compound against multiple coronaviruses including SARS and MERS.

“It also has a strong genetic barrier to development of viral resistance and its oral bioavailability makes it a candidate for use during an outbreak.”

Funds from the National Institute of Allergy and Infectious Diseases (NIAID) supported the development of EIDD-2801.

Emory Institute for Drug Development (EIDD) director and DRIVE CEO George Painter said: “We have been planning to enter human clinical tests of EIDD-2801 for the treatment of influenza and recognised that it has potential activity against the current novel coronavirus.

“Based on the drug’s broad-spectrum activity against viruses including influenza, Ebola and SARS-CoV / MERS-CoV, we believe it will be an excellent candidate.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact